Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox® Antimicrobial Potency Study (ZAPS) in the United States

Diagnostic Microbiology and Infectious Disease

Volumn 40, Issue 1-2, 2001, Pages 59-66

  Jones, Ronald N ^a   Ballow, Charles H ^b   Biedenbach, Douglas J ^a  

^a JMI LABORATORIES   (United States)

^b Buffalo Clinical Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFAZOLIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; NITROFURANTOIN; OXACILLIN; PENICILLIN G; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; STRAIN DIFFERENCE; UNITED STATES;

ACETAMIDES; ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS; MICROBIOLOGY; OXAZOLIDINONES; QUALITY CONTROL; UNITED STATES;

EID: 0034975068     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(01)00235-8     Document Type: Article

References (31)

1. Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin
2. Gram-positive resistance: Challenge for the development of new antibiotics
3. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents
4. Oxazolidinone antibacterial agents
5. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections
6. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
7. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia
8. Emerging resistance to antimicrobial agents in Gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci
9. Oxazolidinones: A review
10. Mechanism of action of DuP-721: Inhibition of an early event during initiation of protein synthesis
11. Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know
12. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
13. The emergent needs for basic research, education, and surveillance of antimicrobial resistance: Problems facing the report from the American Society of Microbiology Task Force on Antibiotic Resistance
14. Antimicrobial activity of quinupristin/dalfopristin (RP 59500, Synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
15. In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: A multicentre international trial
16. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
17. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: Significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999)
18. Vancomycin-resistant enterococci
19. Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay
20. Methicillin-resistant S. Aureus in US hospitals, 1975-1991
21. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci. Enterococcus faecalis, and Enterococcus faecium
22. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid
23. Mechanism of action of the oxazolidinone antibacterial agents
24. Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721
25. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
26. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
27. Practical approach to the identification of clinically relevant Enterococcus species
28. Quality control guidelines for amoxicillin, amoxicillin-clavulanate, Azithromycin, piperacillin/tazobactam, roxithromycin, ticarcillin, ticarcillin/clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials
29. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents